Compare GS & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GS | JNJ |
|---|---|---|
| Founded | 1869 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.5B | 589.2B |
| IPO Year | N/A | 2003 |
| Metric | GS | JNJ |
|---|---|---|
| Price | $786.45 | $243.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $841.00 | $229.89 |
| AVG Volume (30 Days) | 2.2M | ★ 7.0M |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | ★ 2.19% | 2.14% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 11.03 |
| Revenue | N/A | N/A |
| Revenue This Year | $10.70 | $6.63 |
| Revenue Next Year | $4.73 | $7.23 |
| P/E Ratio | ★ $18.19 | $22.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $439.38 | $141.50 |
| 52 Week High | $984.70 | $251.71 |
| Indicator | GS | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 57.85 |
| Support Level | $752.27 | $201.37 |
| Resistance Level | $824.56 | $251.71 |
| Average True Range (ATR) | 30.73 | 4.12 |
| MACD | -8.73 | -1.33 |
| Stochastic Oscillator | 3.27 | 49.94 |
Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a sprawling reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more stable fee-based businesses like asset and wealth management, which comprised roughly 30% of post-provision revenue at the end of 2025. The bank holding company generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.